Adalimumab biosimilar - Oncobiologics

Drug Profile

Adalimumab biosimilar - Oncobiologics

Alternative Names: ONS-3010

Latest Information Update: 17 Nov 2016

Price : $50

At a glance

  • Originator Oncobiologics
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Crohn's disease; Psoriasis; Rheumatoid arthritis; Ulcerative colitis

Highest Development Phases

  • Phase III Plaque psoriasis
  • Phase I Crohn's disease; Psoriasis; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 14 Nov 2016 Final pharmacokinetics, immunogenicity and adverse events data from a phase I trial in Crohn's disease, Psoriasis, Rheumatoid arthritis and Ulcerative colitis released by Oncobiologics
  • 14 Nov 2016 Oncobiologics completes a phase I trial in Crohn's disease, Psoriasis, Rheumatoid arthritis and Ulcerative colitis
  • 16 Jun 2016 Oncobiologics receives clinical trial authorisation approval in United Kingdom, Germany and Spain to conduct a phase III trial in Plaque psoriasis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top